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pts could be divided into two groups according to spirometric values before FESS
(FEV1>70%, mild pulmonary disease, n=7 and FEV1<70%, moderate and severe
pulmonary disease, n=5). One year after FESS, spirometry was unchanged in all
the pts with FEV1>70% with a PEF increase in 2 subjects, while spirometry was
decreased in patients with FEV1<70%, depending on worsening of the pulmonary
status. 1 subject had PEF increase. After FESS the number of hospitalizations in
patients with FEV1>70% was similar to the value observed in the previous year in
the majority of subjects (n=5) or was reduced (n=2) while it was increased in all
the pts with FEV1<70%.
Conclusions: FESS was effective and provided signiﬁcant SND associated symp-
toms relief, with an improvement of the quality of life, despite the possibility of
recurrence. A larger number of pts and a longer follow up period are needed to
evaluate the long term effects of FESS on pulmonary function and to study the
recurrence rate.
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CD infection is a rare though often fatal complication after lung transplantation. In
addition, Sirolimus is deemed to increase infections hazard in these patients.
We basely describe the case of one such patient who was cured thanks to timely
diagnosis and appropriate treatment.
A 39-year-old male CF patient underwent Bilateral Sequential Lung Transplantation
in May 2006. In June 2007 Sirolimus was inclosed in the immunosuppressive
regimen for renal failure.
In July 2007, 3 weeks later, the patient presented with diarrhea, high septic fever
(40º) and abdominal pain. Laboratory tests for inﬂammation were markedly in-
creased and abdominal echography revealed thickening of intestinal walls (20mm);
this ﬁnding was conﬁrmed by MR. Massive ascitis was also present.
Because of the history of Sirolimus administration and the clinical patterns a
diagnosis of CD colitis was suspected and the appropriate therapy was instituted.
Sirolimus was discontinued; 5 Toramix aferesis were performed; Metronidazole
(500mg q6h.) and Meropenem (50mg/kg/die) were administered and support
therapy (blood and plasma transfusion, albumin, total parental nutrition) was started.
The patient moderately improved until positive diagnosis of CD infection was
obtained by stool culture. At this point high dose steroids (1mg/kg per day) were
started. The patient progressively improved and inﬂammation indexes normalized
within 10 days. The patient was discharged asymptomatic 3 weeks after admission
and MR demonstrated reduction of bowel thickness from 20mm to 10mm. The
patient has been in excellent health since then.
In conclusion, if clinically compatible, in patients treated with Sirolimus, a diagnosis
of CD should be suspected and timely treated.
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Herein we report the case of L.D.M. a 16-year-old female affected by CF diagnosed
at two months of life by evocative symptoms and conﬁrmed by positive sweat test;
genotype M1V / del-17a, 17b, 18. Stage 3 neuroblastoma of the right adrenal
gland was diagnosed at the age of 22 months. She received antiblastic therapy
for 4 months following AIEOP NB92 protocol, without a signiﬁcant reduction of
the tumour. AIEOP NB92 protocol was followed by surgical therapy and removal
of 70% of the neoplastic mass. The patient was off therapy after four metabolic
radiotherapeutic cycles with MIBG. At 4 years of age she developed iatrogenic
hypothyroidism treated with thyroxin. At 12 years of age hepatic nodular hyperplasia
was demostrated by abdominal US tomography and conﬁrmed by high resolution
CT (HRCT).
The neuroblastoma and the subsequent therapy did not show any side effects on
the pulmonary function of our patient: chronic colonization by oxacillin susceptible
Staphylococcus aureus, only one sputum positive for Pseudomonas Aeruginosa (in
1993 during immunosuppressive therapy). FEV1 70% of predicted values. Moreover
she maintained an optimal nutritional status (BMI 22.89).
From January to May 2007 three episodes of abdominal pain with icterus, hyper-
transaminasemia and hyperbilirubinemia were reported. Abdominal US tomography
showed only microcholelithiasis, while HRCT showed an increased number and
volume of the hepatic lesions. Normal serum and urinary tumor markers level
(NSE, CA19.9, CEA, VMA and HVA).
MIBG scintigraphy showed accumulated metaiodobenzylguanidine in midline epi-
gastric region. PET scintigraphy ruled out an active disease. These results conﬁrmed
the diagnosis of focal nodular hepatic hyperplasia. No variation was found in the
residual retroperitoneal mass volume (84x67x72mm).
We underline this case of a Cystic Fibrosis patient with previous neuroblastoma
because such a long term follow up (14 years) in a neuroblastoma with a stable
retroperitoneal remaining tumour is so uncommon to be reported.
A multidisciplinary approach was necessary in the differential diagnosis of the
hepatic symptoms because of the coexistence of these two complex pathologies.
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ESBL have the ability to hydrolyse cephalosporins and monobactams, but not
cephamycins or carbapenems. The majority of ESBL-producing organisms have
been reported from hospitalized patients in Intensive Care Units (ICU).
Our experience is about a 47-year-old female pt affected by CF (DF508/DF508),
chronically colonized by mucoid Pseudomonas aeruginosa (PAM) since 1988, in
stable clinical and respiratory conditions (FEV1 40%) until 2005. Her clinical course
was characterized by several lung exacerbations and need for O2 therapy since 2006
and “Non-Invasive Ventilation” since March 2007.
In May 2007, during lung exacerbation treated with iv colistin, amikacin and
ceftazidime, worsening of clinical conditions with severe hypercapnia and acidosis
(pH 7.28; pCO2 88mmHg; HCO−3 35mmol/l) was found and the pt was admitted
in ICU. After one week in ICU, because of clinical improvement (pH 7.368;
pCO2 70.9mmHg; HCO
−
3 39.9mmol/l), the pt was readmitted at the CF center
where started i.v. therapy with ceftazidime, amikacin and ciproﬂoxacin for 3
wks. After a new dramatic worsening of clinical conditions characterized by
fever and dyspnea, a multiresistant ESBL producing strain of EC (106 cfu/ml)
was isolated from sputum. Its antibiotic susceptibility, assessed by disc-diffusion
in Mueller Hinton Agar showed sensibility only to meropenem and fosfomicin
among the 16 tested antibiotics (amikacin, amoxicillin/clavulanate, ampicillin,
aztreonam, cefepime, cefotaxim, cefoxitin, ceftazidime, cefuroxime, ciproﬂoxacin,
fosfomycin, levoﬂoxacin, meropenem, piperacillin/tazobactam, tobramycin and
trimethoprim/sulfametoxazole). ESBL production was conﬁrmed according to CLSI
guidelines. The patient was isolated and changed iv therapy, starting meropenem,
fosfomycin and amikacin, which was performed for 15 days. The patient showed an
immediate clinical improvement and there was a progressive ESBL load reduction
in the sputa, with a simultaneous increase of PAM load to 106 cfu/ml. During
the treatment for EC infection all blood culture taken resulted negative. Although
Enterobacteriaceae are not speciﬁc pathogens in CF, our experience shows that
it’s important to search them in the sputum and to treat. A prompt and speciﬁc
therapy succeeded in eradicating EC ESBL. Collaboration between CF centre and
microbiologists is highlighted!
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Cystic ﬁbrosis (CF) is a chronic hereditary disease with increasing life expectancy
(36.5 years) due to the improvement in patient treatment and assistance. As the CF
population is getting older the incidence of degenerative and malignant diseases is
increasing. We describe a case of thyroid cancer in a female CF 47-year-old patient,
who underwent total thyroidectomy and radioiodine ablation with a positive iodine-
131 uptake in the left lung. In this patient the diffuse pulmonary involvement made
the differential diagnosis between primitive CF disease or metastastic illness difﬁ-
cult. The patient, whose CF diagnosis was performed at the age of 32, presented se-
vere pulmonary involvement and chronic Pseudomonas aeuruginosa infection. Dur-
ing the admission to our CF Adult Centre for a high-dose antibiotic therapy because
of pulmonary exacerbation, a nodular lesion at the right thyroid lobe was detected.
The neck US-scan showed features typical for malignancy without lymph nodal
involvement. Fine needle aspiration of the lesion was positive for papillary thyroid
cancer. The patient, after a high-dose antibiotic IV therapy, underwent total thy-
roidectomy and right lymphadenectomy without surgical nor respiratory complica-
tions. The I-131 whole-body scan, performed after radioiodine ablation of post sur-
gical thyroid remnants, showed two areas of focal I-131 uptake in the left lung. Her
serum thyroglobulin (TG) level and antithyroglobulin antibodies below detection
